JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersTORNTPHARMALKEMIPCALABSAILIFENHNEULANDLABACUTAASNATCOPHARM
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations3,484.23,918.04,147.8
Other Income37.338.360.2
Total Income3,521.53,956.34,207.9
Expenses
+ Cost of Materials Consumed816.3820.0912.4
+ Purchases of Stock-in-Trade412.6497.0477.9
+ Changes in Inventories-46.9-0.4-94.1
+ Employee Benefit Expense601.4687.6772.7
+ Finance Costs44.311.75.6
+ Depreciation & Amortisation138.3171.0182.5
+ Other Expenses803.8882.0971.4
Total Expenses2,769.93,068.93,228.4
EBITDA896.91,031.81,107.4
EBIT758.6860.8924.9
Profit
PBT before Exceptional Items751.5887.4979.5
+ Exceptional Items0.00.0-27.2
Pretax Income751.5887.4952.3
+ Current Tax151.0200.4232.3
+ Deferred Tax47.927.410.6
Tax Expense198.9227.8242.9
Net Income552.6659.6709.5
+ Net Income — Continuing Ops552.6659.6709.5
+ Other Comprehensive Income-14.68.526.8
Total Comprehensive Income538.0668.1736.2
Net Income to Common-14.68.5709.5
Per Share
Basic EPS35.6642.4545.16
Diluted EPS34.8541.5644.45
Other Comprehensive Income — detail
+ Other Comprehensive Income8.526.8
+ Items NOT to be Reclassified to P&L-5.0-5.9-3.6
+ Tax on Items NOT to be Reclassified-1.5-0.9
+ Tax on Items NOT to be Reclassified — alt tag-1.3
+ Items to be Reclassified to P&L-11.513.629.3
+ Tax on Items to be Reclassified0.6-0.2
+ Tax on Items to be Reclassified — alt tag-0.6
Comprehensive Income — Owners of Parent538.0668.126.8
Per Share — as-filed variants
Basic EPS — Continuing Operations35.6642.4545.16
Diluted EPS — Continuing Operations34.8541.5644.45
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit2,302.12,601.42,851.5
Gross Margin %66.0766.4068.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)751.5887.4979.5
− Exceptional Items (reconciliation)0.00.0-27.2
Net Income Adj (tax-effected)552.6659.6729.7
EPS Adj35.6642.4546.45
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.00
Paid Up Equity Capital15.515.616.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.